Quick Answer
Candel Therapeutics, Inc. reported Total Revenue of $125.0 thousand for fiscal year 2022.
Candel Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | $125.0K +0.0% |
$125.0K +0.0% |
$125.0K |
| Revenue (ASC 606) | — | — | — | $125.0K +0.0% |
$125.0K +0.0% |
$125.0K |
| Net Income | -$38.18M +30.8% |
-$55.18M -45.4% |
-$37.94M -101.9% |
-$18.79M +48.0% |
-$36.12M -104.3% |
-$17.68M |
| Diluted EPS | -$0.72 +58.6% |
-$1.74 -32.8% |
-$1.31 -101.5% |
-$0.65 +66.0% |
-$1.91 | — |
| Total Assets | $125.19M +17.2% |
$106.87M +159.4% |
$41.20M -47.0% |
$77.69M -12.9% |
$89.20M +133.0% |
$38.28M |
| Cash and Equivalents | $119.73M +16.6% |
$102.65M +189.9% |
$35.41M -49.5% |
$70.06M -15.2% |
$82.64M +135.8% |
$35.05M |
| Long-Term Debt | — | — | — | — | $560.0K +15.9% |
$483.0K |
| Stockholders Equity | $51.92M -21.7% |
$66.33M +420.4% |
$12.74M -73.3% |
$47.71M -25.6% |
$64.14M +372.2% |
-$23.56M -193.1% |
| R&D Expense | $30.50M +57.9% |
$19.31M -21.2% |
$24.51M +17.9% |
$20.79M +37.0% |
$15.18M +73.4% |
$8.75M |
| Operating Income | -$48.27M -44.6% |
-$33.37M +13.1% |
-$38.39M -10.6% |
-$34.72M -35.0% |
-$25.73M -86.3% |
-$13.81M |
| Shares Outstanding | 54.90M +17.3% |
46.81M +60.9% |
29.09M +0.6% |
28.92M +0.8% |
28.69M +146.6% |
11.64M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2022 | $31.0K | +0.0% | +0.0% |
| Revenue (ASC 606) | September 30, 2022 | $31.0K | +0.0% | +0.0% |
| Net Income | September 30, 2025 | -$11.27M | -5.9% | -135.0% |
| Diluted EPS | September 30, 2025 | -$0.21 | +36.4% | -133.3% |
| Total Assets | September 30, 2025 | $93.60M | +335.0% | -11.7% |
| Cash and Equivalents | September 30, 2025 | $86.96M | +425.2% | -13.6% |
| Long-Term Debt | September 30, 2021 | $541.0K | — | +3.8% |
| Stockholders Equity | September 30, 2025 | $80.12M | +625.2% | -11.2% |
| R&D Expense | September 30, 2025 | $8.46M | +56.2% | +21.0% |
| Operating Income | September 30, 2025 | -$13.21M | -50.8% | -18.2% |
| Shares Outstanding | September 30, 2025 | 54.90M | +70.9% | +0.0% |
- Candel Therapeutics, Inc. reported Total Revenue of $125.0 thousand for fiscal year 2022.
- Candel Therapeutics, Inc. showed an increase of +0.0% in Total Revenue compared to the prior fiscal year.
- Candel Therapeutics, Inc. reported Revenue (ASC 606) of $125.0 thousand for fiscal year 2022.
- Candel Therapeutics, Inc. showed an increase of +0.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Candel Therapeutics, Inc. reported Net Income of -$38.18 million for fiscal year 2025.
- Candel Therapeutics, Inc. showed an increase of +30.8% in Net Income compared to the prior fiscal year.
- Candel Therapeutics, Inc. reported Diluted EPS of $0.72 per share (loss) for fiscal year 2025.
- Candel Therapeutics, Inc. showed an increase of +58.6% in Diluted EPS compared to the prior fiscal year.
- Candel Therapeutics, Inc. reported Total Assets of $125.19 million for fiscal year 2025.
- Candel Therapeutics, Inc. showed an increase of +17.2% in Total Assets compared to the prior fiscal year.
- Candel Therapeutics, Inc. reported Cash and Equivalents of $119.73 million for fiscal year 2025.
- Candel Therapeutics, Inc. showed an increase of +16.6% in Cash and Equivalents compared to the prior fiscal year.
- Candel Therapeutics, Inc. reported Long-Term Debt of $560.0 thousand for fiscal year 2021.
- Candel Therapeutics, Inc. showed an increase of +15.9% in Long-Term Debt compared to the prior fiscal year.
- Candel Therapeutics, Inc. reported Stockholders Equity of $51.92 million for fiscal year 2025.
- Candel Therapeutics, Inc. showed a decrease of -21.7% in Stockholders Equity compared to the prior fiscal year.
- Candel Therapeutics, Inc. reported R&D Expense of $30.50 million for fiscal year 2025.
- Candel Therapeutics, Inc. showed an increase of +57.9% in R&D Expense compared to the prior fiscal year.
- Candel Therapeutics, Inc. reported Operating Income of -$48.27 million for fiscal year 2025.
- Candel Therapeutics, Inc. showed a decrease of -44.6% in Operating Income compared to the prior fiscal year.
- Candel Therapeutics, Inc. reported Shares Outstanding of 54.90 million shares for fiscal year 2025.
- Candel Therapeutics, Inc. showed an increase of +17.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: